|Articles|November 16, 2003
The Anti-VEGF Aptamer Approach: The Macugen Collaborative Trial
Recent results of clinical trials of the anti-VEGF aptamer Macugen (pegaptanibsodium are extremely promising for patients with choroidal neovascularization,said Carmen Puliafito, MD, MBNA, chairman of the Bascom Palmer Eye Institute,Miami.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
























